Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936386 | ISIN: US8006771062 | Ticker-Symbol: GBY
Tradegate
26.07.24
21:04 Uhr
0,825 Euro
+0,032
+4,02 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SANGAMO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SANGAMO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7900,83026.07.
0,7740,80426.07.

Aktuelle News zur SANGAMO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrSangamo rallies for third day in wake of positive gene therapy results12
DoPeering Into Sangamo Therapeutics' Recent Short Interest21
DoCan Pfizer, Sangamo energise haemophilia A gene therapy?32
MiSANGAMO THERAPEUTICS, INC - 8-K, Current Report14
MiWhy Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?17
MiPfizer Hemophilia Gene Therapy Meets Phase 3 Goals, But Its Success Matters More to Sangamo16
MiSangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study13
MiSangamo rises on bleeding disorder gene therapy trial data16
MiPfizer/ Sangamo gene therapy for hemophilia A succeeds in late-stage trial22
MiSangamo Therapeutics, Inc.: Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate248Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today...
► Artikel lesen
05.06.SANGAMO THERAPEUTICS, INC - 8-K, Current Report40
30.05.Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed44
09.05.Sangamo Therapeutics GAAP EPS of -$0.27 misses by $0.05, revenue of $0.48M misses by $5.88M28
09.05.SANGAMO THERAPEUTICS, INC - 8-K, Current Report6
09.05.Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results300RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results. "Sangamo...
► Artikel lesen
09.05.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing375Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale...
► Artikel lesen
25.03.SANGAMO THERAPEUTICS, INC - 8-K, Current Report36
22.03.Sangamo Prices Direct Offering42
22.03.Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall26
22.03.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering600Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4